JP2024502469A - フリードライヒ運動失調症を治療するための方法及び化合物 - Google Patents
フリードライヒ運動失調症を治療するための方法及び化合物 Download PDFInfo
- Publication number
- JP2024502469A JP2024502469A JP2023541510A JP2023541510A JP2024502469A JP 2024502469 A JP2024502469 A JP 2024502469A JP 2023541510 A JP2023541510 A JP 2023541510A JP 2023541510 A JP2023541510 A JP 2023541510A JP 2024502469 A JP2024502469 A JP 2024502469A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutically acceptable
- acceptable salt
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Polyethers (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135427P | 2021-01-08 | 2021-01-08 | |
| US63/135,427 | 2021-01-08 | ||
| PCT/US2022/011560 WO2022150555A2 (en) | 2021-01-08 | 2022-01-07 | Methods and compounds for treating friedreich's ataxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502469A true JP2024502469A (ja) | 2024-01-19 |
| JP2024502469A5 JP2024502469A5 (https=) | 2025-01-09 |
Family
ID=82358799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541510A Pending JP2024502469A (ja) | 2021-01-08 | 2022-01-07 | フリードライヒ運動失調症を治療するための方法及び化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240124491A1 (https=) |
| EP (1) | EP4274583A4 (https=) |
| JP (1) | JP2024502469A (https=) |
| CN (1) | CN117241805A (https=) |
| AR (1) | AR124589A1 (https=) |
| AU (1) | AU2022206424A1 (https=) |
| CA (1) | CA3204523A1 (https=) |
| IL (1) | IL304322A (https=) |
| MX (1) | MX2023008153A (https=) |
| TW (1) | TW202241892A (https=) |
| WO (1) | WO2022150555A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024502469A (ja) * | 2021-01-08 | 2024-01-19 | デザイン セラピューティクス，インク． | フリードライヒ運動失調症を治療するための方法及び化合物 |
| JP2025502064A (ja) * | 2022-01-06 | 2025-01-24 | デザイン セラピューティクス，インク． | フリードライヒ運動失調症を治療するための化合物及び方法 |
| CN119708005A (zh) * | 2023-09-27 | 2025-03-28 | 北京沐华生物科技有限责任公司 | 一类brd4蛋白降解剂化合物及其制备方法和应用 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270727A1 (en) * | 2005-05-03 | 2006-11-30 | Christian Melander | Small molecule therapeutics and uses therefor |
| WO2015074081A1 (en) * | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| WO2017172914A1 (en) * | 2016-03-30 | 2017-10-05 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating frataxin expression |
| JP2018509468A (ja) * | 2015-03-13 | 2018-04-05 | ザ ユニバーシティ オブ ダンディーＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｕｎｄｅｅ | 増殖性、自己免疫性または炎症性疾患の処置に有用な１−［（シクロペンチルまたは２−ピロリジニル）カルボニルアミノメチル］−４−（１，３−チアゾール−５−イル）ベンゼンの誘導体 |
| JP2019511482A (ja) * | 2016-04-15 | 2019-04-25 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| WO2019226836A1 (en) * | 2018-05-22 | 2019-11-28 | Design Therapeutics Inc. | Methods and compounds for the treatment of genetic disease |
| WO2020056188A1 (en) * | 2018-09-12 | 2020-03-19 | Board Of Regents, The University Of Texas System | Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer |
| JP2023516886A (ja) * | 2020-02-03 | 2023-04-21 | デザイン セラピューティクス，インク． | 遺伝性疾患の処置のための方法および化合物 |
| JP2023554317A (ja) * | 2020-12-11 | 2023-12-27 | デザイン セラピューティクス，インク． | 筋強直性ジストロフィー１を調節するための方法及び化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019204781A1 (en) * | 2018-04-20 | 2019-10-24 | Design Therapeutics Inc. | Methods and compounds for the treatment of genetic disease |
| JP2024502469A (ja) * | 2021-01-08 | 2024-01-19 | デザイン セラピューティクス，インク． | フリードライヒ運動失調症を治療するための方法及び化合物 |
-
2022
- 2022-01-07 JP JP2023541510A patent/JP2024502469A/ja active Pending
- 2022-01-07 CA CA3204523A patent/CA3204523A1/en active Pending
- 2022-01-07 AR ARP220100032A patent/AR124589A1/es unknown
- 2022-01-07 EP EP22737158.0A patent/EP4274583A4/en active Pending
- 2022-01-07 US US18/260,549 patent/US20240124491A1/en active Pending
- 2022-01-07 CN CN202280018641.2A patent/CN117241805A/zh active Pending
- 2022-01-07 MX MX2023008153A patent/MX2023008153A/es unknown
- 2022-01-07 WO PCT/US2022/011560 patent/WO2022150555A2/en not_active Ceased
- 2022-01-07 TW TW111100817A patent/TW202241892A/zh unknown
- 2022-01-07 AU AU2022206424A patent/AU2022206424A1/en active Pending
-
2023
- 2023-07-09 IL IL304322A patent/IL304322A/en unknown
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270727A1 (en) * | 2005-05-03 | 2006-11-30 | Christian Melander | Small molecule therapeutics and uses therefor |
| WO2015074081A1 (en) * | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| JP2018509468A (ja) * | 2015-03-13 | 2018-04-05 | ザ ユニバーシティ オブ ダンディーＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｕｎｄｅｅ | 増殖性、自己免疫性または炎症性疾患の処置に有用な１−［（シクロペンチルまたは２−ピロリジニル）カルボニルアミノメチル］−４−（１，３−チアゾール−５−イル）ベンゼンの誘導体 |
| WO2017172914A1 (en) * | 2016-03-30 | 2017-10-05 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating frataxin expression |
| JP2019511482A (ja) * | 2016-04-15 | 2019-04-25 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害剤 |
| WO2019226836A1 (en) * | 2018-05-22 | 2019-11-28 | Design Therapeutics Inc. | Methods and compounds for the treatment of genetic disease |
| WO2020056188A1 (en) * | 2018-09-12 | 2020-03-19 | Board Of Regents, The University Of Texas System | Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer |
| JP2023516886A (ja) * | 2020-02-03 | 2023-04-21 | デザイン セラピューティクス，インク． | 遺伝性疾患の処置のための方法および化合物 |
| JP2023554317A (ja) * | 2020-12-11 | 2023-12-27 | デザイン セラピューティクス，インク． | 筋強直性ジストロフィー１を調節するための方法及び化合物 |
Non-Patent Citations (3)
| Title |
|---|
| BRADBURY,R.H. ET AL.: "Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibito", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 17, JPN6025042284, 2016, pages 7801 - 7817, ISSN: 0005709764 * |
| LAW,R.P. ET AL.: "Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with S", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 10, JPN6025042283, 2018, pages 4317 - 4334, ISSN: 0005709765 * |
| SHEPPARD,G.S. ET AL.: "Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-meth", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 10, JPN6025042282, 2020, pages 5585 - 5623, ISSN: 0005709766 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3204523A1 (en) | 2022-07-14 |
| IL304322A (en) | 2023-09-01 |
| MX2023008153A (es) | 2023-09-21 |
| TW202241892A (zh) | 2022-11-01 |
| AU2022206424A1 (en) | 2023-08-24 |
| AU2022206424A9 (en) | 2024-09-19 |
| WO2022150555A3 (en) | 2022-12-22 |
| CN117241805A (zh) | 2023-12-15 |
| WO2022150555A2 (en) | 2022-07-14 |
| US20240124491A1 (en) | 2024-04-18 |
| EP4274583A4 (en) | 2025-01-22 |
| EP4274583A2 (en) | 2023-11-15 |
| AR124589A1 (es) | 2023-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240050576A1 (en) | Methods and compounds for the treatment of genetic disease | |
| EP4234553A2 (en) | Methods and compounds for the treatment of genetic disease | |
| US20240166693A1 (en) | Methods and compounds for modulating myotonic dystropy 1 | |
| JP2024502469A (ja) | フリードライヒ運動失調症を治療するための方法及び化合物 | |
| JP2025502064A (ja) | フリードライヒ運動失調症を治療するための化合物及び方法 | |
| EP4234550A2 (en) | Methods and compounds for the treatment of genetic disease | |
| EP4234549A1 (en) | Methods and compounds for the treatment of genetic disease | |
| US20230285569A1 (en) | Methods and compounds for the treatment of fragile x | |
| HK40103182A (zh) | 用於治疗弗里德希氏共济失调的方法和化合物 | |
| EP4257128A2 (en) | Methods and compounds for the treatment of genetic disease | |
| HK40116639A (zh) | 用於治疗弗里德希共济失调的化合物和方法 | |
| CN118695861A (zh) | 用于治疗弗里德希共济失调的化合物和方法 | |
| EA049760B1 (ru) | Соединения и способы лечения атаксии фридрейха | |
| HK40104905A (zh) | 用於调节强直性肌营养不良1型的方法和化合物 | |
| HK40090030A (zh) | 用於治疗遗传疾病的方法和化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260311 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260416 |